News
Telix and Regeneron Announce Strategic Radiopharma Collaboration
1+ hour, 33+ min ago (638+ words) Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model. Collaboration combines Telix's expertise in radiopharmaceutical development and manufacturing with Regeneron's leading antibody discovery/development platforms and oncology experience. Telix to receive US$40 million…...
Longhorn Vaccines and Diagnostics Presents New Preclinical Data on Broad-Spectrum Anti-Bacterial Monoclonal Antibody LHNVD-501
1+ week, 6+ day ago (203+ words) Longhorn Vaccines and Diagnostics (LHNVD), an IND enabling-stage biopharmaceutical company, today announced new preclinical data for LHNVD-501, a half-life extended humanized monoclonal antibody. .. - Download the Globe app to my phone or tablet WASHINGTON--(BUSINESS WIRE)--Mar 31, 2026-- Longhorn Vaccines and Diagnostics…...
bio M'rieux Unveils its BIOFIRE" SPOTFIRE" Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing
4+ day, 5+ hour ago (113+ words) ABOUT BIOM'RIEUXPioneering Diagnostics A world leader in the field of in'vitro diagnostics since 1963, bio M'rieux is present in 45'countries and serves more than 160'countries with the support of a large network of distributors. In 2025, revenues reached "4. 1 billion, with over 94% of…...
Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones
2+ week, 2+ day ago (266+ words) March 27, 2026 08: 01 ET "| Source: Glucotrack, Inc. Glucotrack, Inc. "We have also identified a clear U. S. reimbursement pathway that supports a compelling economic profile, built a dual'source U. S. manufacturing strategy with two qualified contract manufacturing partners, and assembled a seasoned management team with deep…...
Eli Lilly and Insilico Medicine Forge $2. 75 Billion AI-Driven Drug Discovery Deal
2+ week, 6+ hour ago (588+ words) Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio San Francisco Suspect Arrested After Molotov Cocktail Attack on Open AI CEO Sam Altman's Home FDA Rejects…...
Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation
3+ week, 6+ day ago (291+ words) March 16, 2026 08: 08 ET "| Source: Fennec Pharmaceuticals Inc. Fennec Pharmaceuticals Inc. Additionally, PEDMARK is recommended for the adolescent and young adult (AYA) population by the National Comprehensive Cancer Network, or NCCN, with a 2 A endorsement. Indications and Usage PEDMARK(sodium thiosulfate injection)…...
Eli Lilly teams up with Insilico to accelerate AI-powered drug development
1+ week, 6+ day ago (320+ words) Eli Lilly and Co (NYSE: LLY) has entered into a drug discovery collaboration with Insilico Medicine, a clinical-stage biotechnology firm focused on generative artificial intelligence, to advance the development of new therapeutics across multiple disease areas, it was announced over…...
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study
1+ week, 4+ day ago (433+ words) Ocugen OCGN announced that enrollment and dosing have been completed in the phase II/III GARDian3 pivotal confirmatory study evaluating its pipeline candidate, OCU410 ST, for the treatment of Stargardt disease. The milestone was achieved in less than nine months, ahead of…...
How The Ocugen (OCGN) Narrative Is Shifting With Retinal Gene Therapy Data And New Valuations
2+ week, 1+ day ago (605+ words) Stay updated as the Fair Value for Ocugen shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Ocugen. Oppenheimer sees Ocugen as an emerging gene therapy player in blinding ocular disorders,…...
FDA's CRL transparency policy is boosting biopharma accountability
2+ hour, 49+ min ago (655+ words) Portions of the CRLs can be redacted, which could lead to some amount of varying interpretation of the information provided," TD Cowen analyst Joe Thome told Bio Space via email. The archived CRLs offered a closer look at historical FDA…...